NCT07093814View on ClinicalTrials.gov

A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

September 2, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

June 30, 2029

Conditions
Glioblastoma
Interventions
DRUG

VRT106

VRT106,intravenous

Trial Locations (1)

Unknown

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

Sponsors
All Listed Sponsors
lead

Guangzhou Virotech Pharmaceutical Co., Ltd.

INDUSTRY

NCT07093814 - A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma | Biotech Hunter | Biotech Hunter